Monument Therapeutics Announces Grant of UK Patent for Neuroinflammation Compound MT1980

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Monument-Therapeutics

More Like This

PR Newswire associated0

Monument Therapeutics Secures £1M Investment to Fund Its Schizophrenia Programme And Drive Next Stage of Growth

PR Newswire associated0

Monument Therapeutics Announces Appointment of Dr Stephen Brannan, Dr Jeff Baker and Dr Mark Treherne to its Advisory Board to Guide Schizophrenia Program

Bionoxx to Highlight Innovative Strategy for Addressing Immune-Related Diseases at 2024 BIO International Conference

TauRx Submits UK Marketing Authorisation Application for HMTM as a Treatment for Alzheimer’s Disease

Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA

Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023

PR Newswire associated0

Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing

Professor Claude Wischik (Photo: Business Wire)

TauRx to Present Two-Year Data from Phase III Trial of HMTM in Alzheimer’s Disease at the AD/PD™ 2024 Conference in March